7 January 2026
GSK announces positive results from B-Well 1 and B-Well 2 phase III trials for bepirovirsen, a potential first-in-class treatment for chronic hepatitis B GSK…
6 January 2026
Exdensur (depemokimab) approved in Japan for severe asthma and chronic rhinosinusitis with nasal polyps GSK plc (LSE/NYSE: GSK) today announced the approval of Exdensur (depemokimab) by Japan’s Ministry…
Prudential announces launch of USD 1.2 billion share buyback programme Prudential plc (the “Company”) announces that it will commence a buyback programme of its…
22 December 2025
Watkin Jones plc (‘Watkin Jones’ or the ‘Group’) Development Partnership for 294-unit hotel in Wimbledon Watkin Jones, the UK’s leading developer and manager of…
LONDONMETRIC PROPERTY PLC LONDONMETRIC TRANSACTS ON £91 MILLION OF INVESTMENT ACTIVITY LondonMetric Property Plc (“LondonMetric”) announces that it has sold £64.4 million of retail assets…
GSK enters agreement with U.S. government to lower drug prices and expand access to respiratory medicines for millions of Americans GSK plc (LSE/NYSE: GSK)…
Enhertu granted Breakthrough Therapy Designation in the US as post-neoadjuvant therapy for patients with HER2-positive early breast cancer Tenth Breakthrough Therapy Designation for AstraZeneca and…
Update on LATIFY Phase III trial of ceralasertib plus Imfinzi in previously treated advanced non-small cell lung cancer The LATIFY Phase III trial of ceralasertib in…